

# **DIABETES AND CARDIOVASCULAR DISEASE**

Etiology, Treatment, and Outcomes

# ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY

Editorial Board:

NATHAN BACK, *State University of New York at Buffalo*

IRUN R. COHEN, *The Weizmann Institute of Science*

DAVID KRITCHEVSKY, *Wistar Institute*

ABEL LAJTHA, *N. S. Kline Institute for Psychiatric Research*

RODOLFO PAOLETTI, *University of Milan*

---

## Recent Volumes in this Series

Volume 491

THE MOLECULAR IMMUNOLOGY OF COMPLEX CARBOHYDRATES—2

Edited by Albert M. Wu

Volume 492

NUTRITION AND CANCER PREVENTION: New Insights into the Role of  
Phytochemicals

Edited under the auspices of the American Institute for Cancer Research

Volume 493

NEUROIMMUNE CIRCUITS, DRUGS OF ABUSE, AND INFECTIOUS DISEASES

Edited by Herman Friedman, Thomas W. Klein, and John J. Madden

Volume 494

THE NIDOVIRUSES (CORONAVIRUSES AND ARTERIVIRUSES)

Edited by Ehud Lavi, Susan R. Weiss, and Susan T. Hingley

Volume 495

PROGRESS IN BASIC AND CLINICAL IMMUNOLOGY

Edited by Andrej Mackiewicz, Jan Zeromski, and Maciej Kurpisz

Volume 496

NONINVASIVE ASSESSMENT OF TRABECULAR BONE ARCHITECTURE AND  
THE COMPETENCE OF BONE

Edited by Sharmila Majumdar, Ph.D., and Brian K. Bay, Ph.D.

Volume 497

INTRACTABLE SEIZURES: Diagnosis, Treatment, and Prevention

Edited by W. McIntyre Burnham, Peter L. Carlen, and Paul A. Hwang

Volume 498

DIABETES AND CARDIOVASCULAR DISEASE: Etiology, Treatment, and Outcomes

Edited by Aubie Angel, Naranjan Dhalla, Grant Pierce, and Pawan Singal

Volume 499

FRONTIERS IN MODELING AND CONTROL OF BREATHING

Edited by Chi-Sang Poon and Homayoun Kazemi

Volume 500

BIOLOGICAL REACTIVE INTERMEDIATES VI: Chemical and Biological Mechanisms  
of Susceptibility to and Prevention of Environmental Diseases

Edited by Patrick M. Dansette, Robert Snyder, Marcel Delaforge, G. Gordon Gibson,  
Helmut Greim, David J. Jollow, Terrence J. Monks, and I. Glenn Sipes

Volume 501

BIOACTIVE COMPONENTS OF HUMAN MILK

Edited by David S. Newburg

---

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

# DIABETES AND CARDIOVASCULAR DISEASE

## Etiology, Treatment, and Outcomes

Edited by

**Aubie Angel**

*Diabetes Research and Treatment Centre  
Winnipeg, Canada*

**Naranjan Dhalla**

*St. Boniface Research Centre  
Winnipeg, Canada*

**Grant Pierce**

*St. Boniface Research Centre  
Winnipeg, Canada*

**Pawan Singal**

*St. Boniface Research Centre  
Winnipeg, Canada*

Springer Science+Business Media, LLC

Library of Congress Cataloging-in-Publication Data

---

Diabetes and cardiovascular disease: etiology, treatment, and outcomes/edited by Aubie Angel ... [et al].  
p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-4613-5496-3 ISBN 978-1-4615-1321-6 (eBook)

DOI 10.1007/978-1-4615-1321-6

1. Diabetic angiopathies. I. Angel, Aubie.

[DNLM]: 1. Diabetes Mellitus—complications—Congresses. 2. Cardiovascular Diseases—etiology—Congresses. WK 835 D53347 2001]

RC700.D5 D525 2001

616.4'62—dc21

2001041362

---

ISBN 978-1-4613-5496-3

©2001 Springer Science+Business Media New York

Originally published by Kluwer Academic / Plenum Publishers, New York in 2001

Softcover reprint of the hardcover 1st edition 2001

10 9 8 7 6 5 4 3 2 1

A C.I.P. record for this book is available from the Library of Congress

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

## **PREFACE**

### **Diabetes and Cardiovascular Disease: from Molecular Processes to Health Policy**

Diabetes and cardiovascular disease together account for the largest portion of health care spending compared to all other diseases in Western society, and the cost continues to increase because of parallel trends including an aging population and an increasing incidence of obesity. In North America, this is most relevant in our First Nations community and other ethnic groups, particularly recent immigrants from the Caribbean and the Indian Subcontinent. Despite expanding knowledge about the importance of insulin resistance in type 2 diabetes mellitus, and autoimmune factors that predispose to type 1 diabetes, etiologic risk factors for cardiovascular complications continue to increase. Much is known about the health risks of obesity, diabetes, hypertension and hyperlipidemia as causal factors in cardiovascular disease, and many of these risk factors can be addressed through a growing array of effective pharmacologic agents. It is also true that behavioral and nonpharmacological strategies are important for individuals and populations. These require behavioral interventions within the community and in individual households. However, our ability to transfer this knowledge and improve lifestyle appears to be rudimentary. It is possible to address this problem by identifying the myriad barriers to a better informed public. Overcoming these barriers will ensure more effective care in the community. In the first instance, an understanding of the causes of diabetes and its cardiovascular complications must be widely appreciated as this will serve as a foundation for evidence based care and wider acceptance of sound science. The International Conference on Diabetes and Cardiovascular Disease, held in Winnipeg in June, 1999, was organized to bring together a multi-disciplinary group of researchers dedicated to further understanding amongst researchers, care givers, and the managers of the health system. The invited speakers were asked to submit their work for publication which served as the basis of this book.

New drugs and nutritional strategies have been developed to improve glycemic control, body weight, and metabolic risk predictors of cardiovascular disease. New interventions, to be valid, require clinical trials in order to establish the effectiveness of specific treatments. These interventions must be tested within the community under ordinary living conditions to confirm their effectiveness. It is our hope that new knowledge reported here will shorten the interval between basic observation, hypothesis testing, clinical trials, and the introduction of new treatments in the community. This should help improve the general well being of society.

The importance of prevention of heart disease cannot be overstated. With heart-health promotion initiatives, communities can be helped by informed provincial and federal policy makers. The work reported here is a compilation of themes that span broad areas of

research relevant to the care of individuals and communities burdened with the disease as well as the costs of health care. It should serve as a valuable reference text for decision makers.

The various chapters include subjects grouped according to major themes that include: 1) epidemiology of diabetes mellitus; 2) metabolic risk factors in diabetes and cardiovascular disease; 3) endothelial function in diabetes; 4) hypertension in diabetes mellitus; 5) cardiac lipid metabolism in diabetes; 6) cardiac function in diabetes; 7) glycemic control and improved cardiovascular function; 8) diabetes management; 9) health promotion in preventing diabetes and its complications; and 10) health policy and national strategies in diabetes. This information should be of interest to scientists studying the cause of diabetes, the clinician concerned with the care of patients with diabetes and cardiovascular disease, and policy makers who help decide priorities for government support.

Finally, we would like to take this opportunity to thank our sponsors and pharmaceutical partners for supporting the conference on which this book is based. We also thank the Institute of Cardiovascular Sciences, St. Boniface General Hospital, and the Diabetes Research and Treatment Centre of Winnipeg for assembling this body of knowledge for the benefit of the patients we serve.

Aubie Angel  
Naranjan Dhalla  
Grant Pierce  
and  
Pawan Singal

# CONTENTS

## EPIDEMIOLOGY AND GENETIC DETERMINANTS OF DIABETES MELLITUS

1. Type 2 Diabetes in Youth: A New Epidemic . . . . .	1
H. Dean	
2. Undiagnosed Diabetes: Burden and Significance in the Canadian Population	7
T. K. Young	
3. Genes, Environment and Diabetes in Canadian Aboriginal Communities . . .	11
R. A. Hegele	
4. Diabetes in Sub-Saharan Africa . . . . .	21
T. J. Aspray and N. Unwin	
5. Coronary Heart Disease and Risk Factors in Asian Indians . . . . .	27
M. Chandalia and P. C. Deedwania	

## METABOLIC RISK FACTORS IN DIABETES AND CARDIOVASCULAR DISEASE

6. The Plasma Glucose Level—A Continuous Risk Factor for Vascular Disease in Both Diabetic and Non-Diabetic People . . . . .	35
H. C. Gerstein	
7. Modified Lipoproteins and Cardiovascular Risk . . . . .	41
W. Aldahi and J. Frohlich	
8. Advances in Lipid-Lowering Therapy in Atherosclerosis . . . . .	49
J. Davignon	
9. Homocysteine as a Risk Factor in Cardiovascular Disease . . . . .	59
D. E. C. Cole	

10. Endothelial Integrity and Repair .....	65
T. J. Lee, S. Noria, J. Lee, and A. I. Gotlieb	
11. Molecular Mechanisms of Endothelial Dysfunction in the Diabetic Heart ...	75
P. Rösen, X. Du, and G. Z. Sui	
12. A Study of Vascular Wound Healing in a Rabbit Model of Type I Diabetes	87
N. K. Schiller, D. L. Akers, B. Burke, A. M. Timothy, B. Bedi, and D. B. McNamara	
13. Endothelins in the Microvasculature and Heart in Diabetes .....	97
S. Chakrabarti, S. Chen, T. Evans, and M. Karmazyn	
14. Diabetes and Endothelial Function: Implications for Coronary Angioplasty	109
T. J. Anderson	

### **HYPERTENSION AND DIABETES MELLITUS**

15. The Effect of Hypertension in Diabetes .....	115
E. D. Burgess	
16. The Diabetic Hypertensive (or Hypertensive Diabetic)—A Compelling Need to Optimize Blood Pressure .....	119
S. G. Carruthers	
17. Left Ventricular Diastolic Dysfunction in Diabetic or Hypertensive Subjects: Role of Collagen Alterations .....	127
T. J. Regan, G. N. Jyothirmayi, C. Laham, and A. Jain	
18. Alterations in the Vascular Actions of Insulin in the Pathogenesis of Insulin Resistance and Hypertension .....	133
S. Verma and J. H. McNeill	
19. Cardiac Hypertrophy in Diabetes Patients with and without Hypertension: Effects of Troglitazone, a Novel Antidiabetic Drug, on Diastolic Function ..	143
N. Makino, H. Hirayama, H. Yonemochi, K. Yano, and N. Abe	
20. Cost and Benefits of Blood Pressure Monitoring and Control .....	149
A. Chockalingam and N. R. C. Campbell	

### **CARDIAC LIPID METABOLISM IN DIABETES**

21. Malonyl CoA Control of Fatty Acid Oxidation in the Diabetic Rat Heart ..	155
G. D. Lopaschuk	



22. Alterations in 1,2-Diacylglycerol and Ceramides in Diabetic Rat Heart . . . . . 167  
K. Okumura, K. Hayashi, K. Murase, H. Matsui, and Y. Toki

23. Regulation of Myocardial Phospholipid N-Methylation by Insulin and Diabetes . . . . . 175  
S. W. Schaffer and M. Mozaffari

24. Reduction of Phosphatidylinositol-4,5-Bisphosphate Mass in Heart Sarcolemma during Diabetic Cardiomyopathy . . . . . 183  
P. S. Tappia, S. Liu, Y. Tong, S. Ssenyange, and V. Panagia

25. Tumor Necrosis Factor- $\alpha$ , Sphingomyelinase and Ceramides Activate Tyrosine Kinase, p21Ras and Phosphatidylinositol 3-Kinase: Implications for Glucose Transport and Insulin Resistance . . . . . 191  
A. N. Hanna, J. Xu, and D. N. Brindley

**CARDIAC FUNCTION AND OXIDATIVE STRESS IN DIABETES**

26. Antioxidants, Free Radical Stress and Diabetes . . . . . 201  
S. S. Rastogi and R. B. Singh

27. Oxidative Stress and Functional Deficit in Diabetic Cardiomyopathy . . . . . 213  
P. K. Singal, A. Belló-Klein, F. Farahmand, and V. Sandhawalia

28. Ketosis and the Generation of Oxygen Radicals in Diabetes Mellitus . . . . . 221  
S. K. Jain and K. Kannan

29. Effect of Diabetes Mellitus on Hemodynamic and Cardiometabolic Correlates in Experimental Myocardial Infarction . . . . . 229  
S. K. Gupta, D. S. Arya, U. Singh, and K. K. Talwar

30. Cardiac Function in Perfused Hearts from Diabetic Mice . . . . . 241  
D. D. Belke, T. S. Larsen, and D. L. Severson

31. Mg<sup>2+</sup>-Dependent Atpase Activity in Cardiac Myofibrils from the Insulin-Resistant Jcr:La-Cp Rat . . . . . 247  
T. Misra, J. C. Russell, T. A. Clark, and G. N. Pierce

32. Cyclic Nucleotide Phosphodiesterase Families in Intracellular Signaling and Diabetes . . . . . 253  
A. Lugnier

33. Alterations in G-Protein-Linked Signal Transduction in Cardiovascular Vascular Smooth Muscle in Diabetes . . . . . 263  
M. B. Anand-Srivastava, R. Wang, and Y. Y. Liu

## **GLYCEMIC CONTROL AND IMPROVED CARDIOVASCULAR FUNCTION**

- |   |     |
|---|-----|
| 34. Mechanism of HDL Lowering in Insulin Resistant States . . . . .   | 273 |
| G. F. Lewis, S. Rashid, K. D. Uffelman, and B. Lamarche   |     |
| 35. Insulin Treatment Post Myocardial Infarction: The Digami Study . . . . .  | 279 |
| K. Malmberg, A. Norhammar, and L. Rydén   |     |
| 36. Response to Ischemia and Endogenous Myocardial Protection in the<br>Diabetic Heart . . . . .  | 285 |
| T. Ravingerova, R. Stetka, M. Barancik, K. Volkovova, D. Pancz,<br>A. Ziegelhöffer, and J. Styk   |     |
| 37. Type 2 Diabetes: Pharmacological Intervention in an Animal Model . . . . .  | 295 |
| J. C. Russell   |     |
| 38. The Diabetic Heart and Cardiac Glycosides . . . . .   | 303 |
| M. Nagano   |     |
| 39. Hyperglycemia-Induced Protein Kinase Signaling Pathways in Vascular<br>Smooth Muscle Cells: Implications in the Pathogenesis of Vascular<br>Dysfunction in Diabetes . . . . . | 311 |
| A. K. Srivastava  |     |
| 40. Regulation of Myocardial and Skeletal Muscle Na,K-ATPase in Diabetes<br>Mellitus in Humans and Animals . . . . .  | 319 |
| H. Bundgaard and K. Kjeldsen  |     |

## **DIABETES MANAGEMENT— A MULTIDISCIPLINARY APPROACH**

- |  |     |
|--|-----|
| 41. Food Strategies for Diabetes and Heart Health . . . . .  | 323 |
| K. Camelon   |     |
| 42. The Atherosclerosis Reversal Clinic: The Way of the Future . . . . .                                     | 331 |
| K. J. Kingsbury and J. Frolich   |     |
| 43. Lipid Clinics/Cardiovascular Risk Reduction Clinics: Current State and<br>Future Consideration . . . . . | 337 |
| J. Frohlich and K. Kingsbury   |     |
| 44. Amputation Prevention and Rehabilitation in Diabetes . . . . .   | 349 |
| J. M. Embil  |     |

45. Laboratory Testing in Diabetes Mellitus ..... 359  
M. Leroux

**HEALTH PROMOTION IN PREVENTING  
DIABETES AND ITS COMPLICATIONS**

46. Diabetes and Cardiovascular Disease ..... 367  
B. O'Connor

47. Prevalence of Cardiovascular Risk Factors in Canadians with Diabetes  
Mellitus ..... 373  
D. R. MacLean, M. R. Joffres, M. H. Tan, and A. Petrasovits

48. G7 Project Promoting Heart Health ..... 381  
J. L. O'Loughlin, A. C. Edwards, S. Elliott, and A. Petrasovits

49. Canadian Heart Health Initiative: Research Review ..... 385  
D. Harvey

**HEALTH POLICY AND NATIONAL  
STRATEGIES IN DIABETES**

50. Putting Policy into Action ..... 389  
S. M. MacDonald

51. National and International Strategies to Prevent Obesity and Diabetes ..... 393  
B. A. Reeder

52. The Diabetes Council of Canada (DCC): Coordinating National Diabetes  
Strategies ..... 401  
N. W. Rodger

53. The Federal Government and Diabetes: An Incremental Process ..... 405  
W. P. Mickelson